174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)?

Saved in:
Bibliographic Details
Title: 174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)?
Authors: Itzykson, R., Thepot, S., Beyne-Rauzy, O., Ame, S., Isnard, F., Salanoubat, C., Taksin, A.-L., Chelgoum, Y., Quesnel, B., Malfuson, J.-V., Legros, L., Vey, N., Turlure, P., Gardin, C., Boehrer, S., Ades, L., Fenaux, P.
Source: Leukemia Research. Jan2011 Supplement 1, Vol. 35, pS68-S68. 1p.
Database: Academic Search Ultimate
Description
ISSN:01452126
DOI:10.1016/S0145-2126(11)70176-X